Eyeworld

Advanced therapeutic and surgical options to eliminate post-cataract surgery inflammation and pain Supplement to EyeWorld July 2016 continued on page 2 Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Edu- cation through the joint providership of the American Society of Cataract & Refractive Surgery (ASCRS) and EyeWorld. ASCRS is accredited by the ACCME to provide continuing medical education for physicians. Educational Objectives Ophthalmologists who participate in this activity will: • Distinguish predisposing factors putting patients at higher risk for an inflammatory reaction after cataract surgery, including key uveitis, retina, and corneal issues • Identify the true impact of ocular inflammation levels on outcomes in refractive cataract surgery: variability in visual acuity and quality results; delayed visual recovery that reduces the postop- erative "wow" factor; pain and discomfort that reduce patient satisfaction • Develop personal protocol for acceptable levels of inflammation for post-cataract surgery, as guided by ASCRS leadership • Identify new agents and acquire strategies to eliminate inflammation and relieve pain by maximizing the penetration of anti-inflammatory agents into target tissues, including: dosing lev- els, interventional timing, concomitant therapies and duration to address ocular inflammation; key vehicle parameters including viscosity and other key considerations in selecting the appropriate formulation; and patient adherence to regimen • Assess the clinical impact of various levels of ultrasound energy applied during cataract surgery, and how these differ with complex vs. routine cataract patients, and recognize the amount of reduction in these levels available Designation Statement The American Society of Cataract & Refractive Sur- gery designates this enduring materials educational activity for a maximum of 1.0 AMA PRA Category 1 Credits. ™ Physicians should claim only credit commensurate with the extent of their participation in the activity. Claiming Credit To claim credit, participants may visit bit.ly/28N3jDJ to review content and download the post-activity test and credit claim. All participants must pass the post-activity test with a score of 75% or higher to earn credit. Alternatively, the post-test form included in this supplement may be faxed to the number indicated for credit to be awarded, and a certificate will be mailed within 2 weeks. When viewing online or downloading the material, standard Internet access is required. Adobe Acrobat Reader is needed to view the materials. CME credit is valid through January 31, 2017. CME credit will not be awarded after that date. Notice of Off-Label Use Presentations This activity may include presentations on drugs or devices or uses of drugs or devices that may not have been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. ADA/Special Accommodations ASCRS and EyeWorld fully comply with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. Any participant in this educational program who requires special accommodations or services should contact Laura Johnson at ljohnson@ascrs.org or 703-591- 2220. Financial Interest Disclosures Eric Donnenfeld, MD, has an investment interest in and has received a retainer, ad hoc fees, or other consulting income from: Abbott Medical Optics, Acu- Focus, Alcon Laboratories, Allergan, AqueSys, Bausch + Lomb, Beaver Visitec International, CRST, Glaukos, Icon Bioscience, Kala Pharmaceuticals, Katena, Mati Pharmaceuticals, Merck Sharp & Dohme, Mimetogen, NovaBay Pharmaceuticals, Novaliq, OcuHub, Odyssey, Omeros, Pfizer, PRN, RPS, Shire, and Straths. Edward Holland, MD, has received a retainer, ad hoc fees, or other consulting income from: Alcon, Bausch + Lomb, Kala Pharmaceuticals, Mati Therapeutics, PRN, RPS, Senju, Shire, TearScience, and TearLab. He is a member of the speakers bureau of: Alcon, Bausch + Lomb, Kala, Mati, RPS, Senju, and TearLab. Dr. Holland has received research funding from Alcon, Mati, PRN, and Senju, and has received travel expense reimbursement from Alcon and Bausch + Lomb. Terry Kim, MD, has received a retainer, ad hoc fees, or other consulting income from and has an invest- ment interest in Ocular Therapeutix and Omeros. He has received a retainer, ad hoc fees or other consult- ing income from and is a member of the speakers bureau of Alcon and Bausch + Lomb. Dr. Kim has received a retainer, ad hoc fees, or other consulting income from: Acucela, Acuity Advisors, Allergan, CoDa Therapeutics, Foresight Biotherapeutics, Kala, NovaBay, Ocular Systems Inc., Oculeve, PowerVision, Presbyopia Therapies, Shire, Stealth BioTherapeutics, TearLab, and TearScience. Richard Lindstrom, MD, has received a retainer, ad hoc fees, or other consulting income and has an investment interest in: 3D Vision Systems, Abbott Medical Optics, AcuFocus, BioSyntrx, Broad- Spot, Bruder, Calhoun Vision, Clarity Ophthalmics, Clear Sight, EBV Partners, EGG Factory Ventures, Encore Vision, Equinox, Evision Photography, Eyemaginations, Glaukos, High Performance Optics, LENSAR, LifeGuard Health, Minnesota Eye Consultants, NovaBay, NuLens, Ocular Optics, Ocular Therapeutix, Omega Eye Health, Photo EyeWear, Revi- talVision, Schroder Life Science Venture, Sightpath, TearLab, Tracey Technologies, Transcend Medical, and TrueVision. He has an investment interest in: Confluence Acquisition Partners, CXL Ophthalmics, Evision Medical Laser, Foresight Venture Fund #3, FzioMed, Healthcare Transaction Services, Heaven Fund, OnPoint, Rainwater Healthcare, Refractec, and Viradax. Dr. Lindstrom has received a retainer, ad hoc fees, or other consulting income from: Advanced Refractive Technologies, Alcon, Elenza, ForSight Labs, NASA-Vision for Mars Program, Nicox, OSN, Oculeve, Omeros, Versant, and Vision Solution Technologies. He earns a royalty or derives other financial gain from, has received a retainer, ad hoc fees, or other consulting income from, and has an investment inter- est in Bausch + Lomb, and earns a royalty or derives other financial gains from and has an investment interest in Quest. Francis Mah, MD, has received a retainer, ad hoc fees, or other consulting income from, is a member of the speakers bureau of, and has received research funding and travel reimbursement from: Abbott Medical Optics, Alcon, Allergan, Bausch + Lomb, and Shire. He has received a retainer, ad hoc fees, or other consulting income from: CoDa Therapeutics, ForSight Labs, NovaBay Pharmaceuticals, Ocular Therapeutix, and TearLab. Dr. Mah has received research funding from Ocular Therapeutix. Staff members: Laura Johnson has no ophthalmic- related financial interests. Beth Marsh has received a retainer, ad hoc fees, or other consulting income from Akorn and Shire. The survey demonstrat- ed that more than half (52%) of respondents who prescribe NSAIDs for the average cataract patient discontinue them 4 patterns. The survey collected responses from 2,047 unique respondents, based on 485 data points centered on the most compelling and controversial issues facing ophthalmologists. T o ensure successful outcomes from cat- aract surgery, it is critically important to recognize the influence of ocular inflammation on sur- gical results. In this supplement, we will examine the impact of inflam- mation as well as therapeutic strategies to help you achieve the excellent visual outcomes your patients expect from cata- ract surgery. Survey results Results from the 2015 ASCRS Clinical Survey provided key insights regarding members' clinical opinions and practice ASCRS Clinical Survey demonstrates members' clinical practices by Richard Lindstrom, MD Achieving excellent visual outcomes from cataract surgery " Although other medical fields largely use generic medications, ophthalmologists still prescribe numerous branded drugs. " –Richard Lindstrom, MD Richard Lindstrom, MD Supported by Alcon Laboratories, Bausch + Lomb, Imprimis Pharmaceuticals, Ocular Therapeutix, and Omeros Corporation Click to read and claim CME credit

• Cover